busulfan has been researched along with Anemia, Fanconi in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the mid-1990s, we introduced a fludarabine (Flu)-based conditioning regimen for hematopoietic stem cell transplantation (HSCT) in patients with Fanconi anemia (FA)." | 7.77 | Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning. ( Balashov, D; Brooks, R; Maschan, A; Or, R; Resnick, IB; Revel-Vilk, S; Rheingold, L; Shapira, MY; Skorobogatova, E; Stein, J; Stepensky, P; Trakhtman, P; Weintraub, M, 2011) |
| "It is well known that pharmacokinetics (PK)-guided busulfan (BU) dosing increases engraftment rates and lowers hepatotoxicity in patients undergoing hematopoietic cell transplantation (HCT)." | 5.51 | Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different? ( Boulad, F; Davies, SM; Emoto, C; Fukuda, T; Fuller, K; Mehta, PA; Seyboth, B; Teusink-Cross, A; Vinks, AA; Wilhelm, J, 2019) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate." | 5.19 | Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. ( Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE, 2014) |
| "In the mid-1990s, we introduced a fludarabine (Flu)-based conditioning regimen for hematopoietic stem cell transplantation (HSCT) in patients with Fanconi anemia (FA)." | 3.77 | Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning. ( Balashov, D; Brooks, R; Maschan, A; Or, R; Resnick, IB; Revel-Vilk, S; Rheingold, L; Shapira, MY; Skorobogatova, E; Stein, J; Stepensky, P; Trakhtman, P; Weintraub, M, 2011) |
| "Busulfan levels were monitored to avoid excess toxicity." | 2.84 | Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. ( Baker, KS; Boulad, F; Davies, SM; Guinan, E; Kernan, NA; Lane, A; Leemhuis, T; Lehmann, L; Margolis, D; Mehta, PA; Myers, K; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Williams, DA, 2017) |
| "It is well known that pharmacokinetics (PK)-guided busulfan (BU) dosing increases engraftment rates and lowers hepatotoxicity in patients undergoing hematopoietic cell transplantation (HCT)." | 1.51 | Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different? ( Boulad, F; Davies, SM; Emoto, C; Fukuda, T; Fuller, K; Mehta, PA; Seyboth, B; Teusink-Cross, A; Vinks, AA; Wilhelm, J, 2019) |
| "Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects." | 1.36 | Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. ( Amini, M; Ghavamzadeh, A; Hadjibabaie, M; Hamedani, R; Hamidieh, AA; Sadrai, S, 2010) |
| "Twenty-three patients developed a malignancy 1." | 1.29 | Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. ( Deeg, HJ; Devergie, A; Gluckman, E; Henry-Amar, M; Schoch, G; Socié, G; Storb, R; Sullivan, KM; Witherspoon, RP, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Voter, AF | 1 |
| Manthei, KA | 1 |
| Keck, JL | 1 |
| Rostami, T | 1 |
| Mousavi, SA | 2 |
| Kiumarsi, A | 1 |
| Kasaeian, A | 1 |
| Rad, S | 1 |
| Yaghmaie, M | 1 |
| Ghavamzadeh, A | 2 |
| Xu, L | 1 |
| Lu, Y | 1 |
| Hu, S | 1 |
| Li, C | 1 |
| Tang, Y | 1 |
| Wang, H | 1 |
| Yan, J | 1 |
| Chen, J | 1 |
| Liu, S | 1 |
| Sun, Y | 1 |
| Wu, X | 1 |
| Lin, F | 1 |
| Lu, P | 1 |
| Huang, X | 1 |
| van Hoogdalem, MW | 1 |
| Emoto, C | 2 |
| Fukuda, T | 2 |
| Mizuno, T | 1 |
| Mehta, PA | 3 |
| Vinks, AA | 2 |
| Hou, H | 1 |
| Yao, YH | 1 |
| Lu, J | 1 |
| Xiao, PF | 1 |
| Bian, XN | 1 |
| Liu, H | 1 |
| Hu, DX | 1 |
| Ling, J | 1 |
| Li, J | 1 |
| Zhai, Z | 1 |
| Kong, LJ | 1 |
| Hu, SY | 1 |
| Seyboth, B | 1 |
| Teusink-Cross, A | 1 |
| Davies, SM | 2 |
| Wilhelm, J | 1 |
| Fuller, K | 1 |
| Boulad, F | 3 |
| Burroughs, LM | 1 |
| Nemecek, ER | 1 |
| Torgerson, TR | 1 |
| Storer, BE | 1 |
| Talano, JA | 1 |
| Domm, J | 1 |
| Giller, RH | 1 |
| Shimamura, A | 1 |
| Delaney, C | 1 |
| Skoda-Smith, S | 1 |
| Thakar, MS | 1 |
| Baker, KS | 2 |
| Rawlings, DJ | 1 |
| Englund, JA | 1 |
| Flowers, ME | 2 |
| Deeg, HJ | 3 |
| Storb, R | 3 |
| Woolfrey, AE | 1 |
| Anur, P | 1 |
| Friedman, DN | 1 |
| Sklar, C | 1 |
| Oeffinger, K | 1 |
| Castiel, M | 1 |
| Kearney, J | 1 |
| Singh, B | 1 |
| Prockop, SE | 2 |
| Kernan, NA | 2 |
| Scaradavou, A | 2 |
| Kobos, R | 1 |
| Curran, K | 1 |
| Ruggiero, J | 1 |
| Zakak, N | 1 |
| O'Reilly, RJ | 3 |
| Leemhuis, T | 1 |
| Myers, K | 1 |
| Williams, DA | 1 |
| Lehmann, L | 1 |
| Guinan, E | 1 |
| Margolis, D | 1 |
| Lane, A | 1 |
| Hamidieh, AA | 1 |
| Hamedani, R | 1 |
| Hadjibabaie, M | 1 |
| Amini, M | 1 |
| Sadrai, S | 1 |
| Stepensky, P | 1 |
| Shapira, MY | 2 |
| Balashov, D | 1 |
| Trakhtman, P | 1 |
| Skorobogatova, E | 1 |
| Rheingold, L | 1 |
| Brooks, R | 1 |
| Revel-Vilk, S | 1 |
| Weintraub, M | 1 |
| Stein, J | 1 |
| Maschan, A | 1 |
| Or, R | 2 |
| Resnick, IB | 2 |
| Maschan, AA | 2 |
| Trakhtman, PE | 1 |
| Balashov, DN | 1 |
| Shipicina, IP | 1 |
| Skorobogatova, EV | 2 |
| Skvortsova, YV | 1 |
| Dyshlevaja, ZM | 1 |
| Samochatova, EV | 2 |
| Rumiantsev, AG | 1 |
| Torjemane, L | 1 |
| Ladeb, S | 1 |
| Ben Othman, T | 1 |
| Abdelkefi, A | 1 |
| Lakhal, A | 1 |
| Ben Abdeladhim, A | 1 |
| Bitan, M | 1 |
| Aker, M | 1 |
| Ackerstein, A | 1 |
| Samuel, S | 1 |
| Elad, S | 1 |
| Slavin, S | 1 |
| Socié, G | 1 |
| Schoch, G | 1 |
| Henry-Amar, M | 1 |
| Witherspoon, RP | 2 |
| Devergie, A | 1 |
| Sullivan, KM | 2 |
| Gluckman, E | 1 |
| Kryzanovskii, OI | 1 |
| Yourlova, MI | 1 |
| Pashanov, ED | 1 |
| Potapova, YE | 1 |
| Timonova, LA | 1 |
| Bogatcheva, NY | 1 |
| Roumjantzev, AG | 1 |
| Doney, KC | 1 |
| Sanders, JE | 1 |
| Bryant, E | 1 |
| Appelbaum, FR | 1 |
| Buckner, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine[NCT00987480] | Phase 2 | 45 participants (Actual) | Interventional | 2009-09-25 | Completed | ||
| A Phase I/II Feasibility Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells[NCT03538899] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2018-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Defined as time from date of transplant to relapse, graft rejection or graft failure, or death.~Primary non-engraftment is diagnosed when the participants fails to achieve an ANC >/= 500/ul at any time in the first 28 days post-transplant.~For participants with MDS or AML, relapse will be analyzed as to type and genetic origin of the MDS/leukemic cells. These will be defined by an increasing number of blasts in the marrow over 5% by the presence of circulating peripheral blasts, or by the presence of blasts in any extramedullary site. Cytogenetic analysis of the marrow and/or peripheral blood will also be obtained for the diagnosis of relapse." (NCT00987480)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 77.8 |
Overall Survival is defined as time from date of transplant to event (death from any cause) or last follow-up. (NCT00987480)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 80 |
(NCT00987480)
Timeframe: 100 days
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 6.7 |
(NCT00987480)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 0 |
1 review available for busulfan and Anemia, Fanconi
| Article | Year |
|---|---|
Allogenic bone marrow transplantation: current status and future directions.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Cell Separation; Cyclophosphamide; Erythroc | 1983 |
2 trials available for busulfan and Anemia, Fanconi
| Article | Year |
|---|---|
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulf | 2014 |
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; Child; Child, Preschool; Cyclophosph | 2017 |
15 other studies available for busulfan and Anemia, Fanconi
| Article | Year |
|---|---|
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
Topics: Antineoplastic Agents; DNA Damage; DNA Helicases; DNA Repair; Drug Screening Assays, Antitumor; Fanc | 2016 |
Radiation-free reduced-intensity hematopoietic stem cell transplantation with in vivo T-cell depletion from matched related and unrelated donors for Fanconi anemia: prognostic factor analysis.
Topics: Busulfan; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Pr | 2022 |
Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
Topics: Bone Marrow; Busulfan; Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem C | 2022 |
Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients.
Topics: Alkylating Agents; Body Composition; Busulfan; Child; Fanconi Anemia; Female; Hematopoietic Stem Cel | 2020 |
[Treatment of four cases of Fanconi anemia by allogeneic hematopoietic stem cell transplantation with low intensity conditional regimen].
Topics: Busulfan; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Tr | 2018 |
Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?
Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Fanconi Anemia; Female; Hematopoie | 2019 |
Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Fanconi Anemia; Hematopoietic Stem Cell Transp | 2016 |
Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Dose-Response | 2010 |
Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2011 |
Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegaloviru | 2004 |
Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2006 |
Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; | 2006 |
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, Pres | 1996 |
Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.
Topics: Alkylating Agents; Anemia, Refractory, with Excess of Blasts; Bone Marrow Transplantation; Busulfan; | 1997 |
Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1992 |